Clinical Trials
19 Parkinson Trials Now Recruiting Across the US
A comprehensive database tracks 19 actively recruiting clinical trials for Parkinson's disease as of May 2026. Studies cover gene therapy, neuroprotective agents, and novel drug delivery systems. Eligibility criteria are available in plain English, with full sponsor and phase information included. Patients can filter by location, age, and disease stage to find appropriate studies.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Patients can filter by location, age, and disease stage to find appropriate studies.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Over 430 Parkinson's Trials Listed on ClinicalTrials.gov
The total count of recruiting Parkinson's disease trials has grown to 430+ studies globally. These span Phase I through Phase IV and include trials for motor symptoms, non-motor symptoms, and disease-modifying therapies. Researchers emphasize that participation helps advance the entire field and may provide access to cutting-edge treatments not yet available outside trial settings.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Researchers emphasize that participation helps advance the entire field and may provide access to cutting-edge treatments not yet available outside trial settings.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Join the PD GENEration Registry
The Parkinson's Foundation's PD GENEration study has enrolled over 30,000 patients to map genetic factors in Parkinson's disease. The registry collects blood samples to identify genetic predispositions — approximately 10-15% of PD cases have an identifiable genetic cause. Participants contribute to a shared data pool that accelerates research toward precision medicine approaches.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Participants contribute to a shared data pool that accelerates research toward precision medicine approaches.
Limit: A genetic association does not determine an individual’s future and does not mean a targeted therapy is available.
Breakthrough Treatments
Tavapadon: FDA Application Filed for Next-Generation Dopamine Therapy
AbbVie has submitted a New Drug Application to the FDA for tavapadon, a once-daily pill targeting motor symptoms. Unlike traditional dopamine agonists that bind primarily to D2/D3 receptors, tavapadon is a partial agonist of D1 and D5 receptors — a different binding profile that may reduce side effects like excessive daytime sleepiness, compulsivity, and psychosis. The application is based on the TEMPO-1, 2, and 3 clinical trials, which showed meaningful improvements in motor control and daily function.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The application is based on the TEMPO-1, 2, and 3 clinical trials, which showed meaningful improvements in motor control and daily function.
Limit: Results from cells or animals may not reproduce in people.
Bemdaneprocel: Stem Cell Therapy Enters Final Trial Phase
A stem cell therapy called bemdaneprocel is moving into late-stage trials. The approach aims to replace lost dopamine-producing brain cells through transplanted stem cell-derived neurons. If successful, it would represent a disease-modifying treatment rather than just symptom management — a significant departure from current therapies. The therapy is being developed as a potential cure-oriented approach complementary to药物治疗.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The therapy is being developed as a potential cure-oriented approach complementary to药物治疗.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Case Western Discovery: New Protein Interaction Blocked in Preclinical Models
Researchers at Case Western Reserve University identified a harmful protein interaction that disrupts the brain's cellular energy production in Parkinson's disease. The study, published in Molecular Neurodegeneration, found that alpha-synuclein abnormally binds to an enzyme called ClpP, damaging mitochondria in dopamine-producing neurons. A targeted treatment blocking this interaction restored brain cell function in experimental models.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: A targeted treatment blocking this interaction restored brain cell function in experimental models.
Limit: Results from cells or animals may not reproduce in people.
Lifestyle Interventions
2026 Exercise Guidelines Updated for Parkinson's
The Parkinson's Foundation, in collaboration with the American College of Sports Medicine, issued updated exercise guidelines building on the 2022 release. The new recommendations include revised guidance on exercise type and frequency based on the latest research, with expanded recommendations for aquatic therapy, balance training, and community-based programs.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: The new recommendations include revised guidance on exercise type and frequency based on the latest research, with expanded recommendations for aquatic therapy, balance training, and community-based programs.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
UT Health Researcher Studies Exercise + VR for Motor Learning
A researcher at UT Health San Antonio is studying how combining exercise with virtual reality games affects motor learning in Parkinson's patients. The study investigates whether dual-task training — exercising while navigating virtual environments — improves neuroplasticity and motor function more than exercise alone. Early evidence suggests that cognitively engaged physical activity may amplify benefits.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Early evidence suggests that cognitively engaged physical activity may amplify benefits.
Limit: The report does not provide enough context to turn this headline into medical advice.
Physical Exercise for Fatigue: January 2026 Meta-Analysis
A systematic review published in January 2026 found moderate-certainty evidence that physical exercise — particularly continuous aerobic modalities like walking — effectively reduces fatigue in Parkinson's disease. The analysis of multiple clinical trials reinforces that exercise is medicine for PD, with benefits across both motor and non-motor symptoms.
Systematic reviewLevel: Synthesized evidenceCombines multiple studiesWhat the study tells us: The analysis of multiple clinical trials reinforces that exercise is medicine for PD, with benefits across both motor and non-motor symptoms.
Limit: The conclusion depends on the quality and differences among the included studies; it cannot predict an individual outcome.
Emerging Research
UConn Testing Novel Anti-Inflammatory Pill in Early Parkinson's
A clinical trial at UConn Health is testing whether a novel anti-inflammatory pill can slow Parkinson's progression in newly diagnosed patients. The approach targets neuroinflammation as a driver of disease progression, distinct from dopamine replacement. One patient, Bill, described his experience: diagnosed in his fifties after a physical therapist noticed a twitching thumb, he now runs, does yoga, and has enrolled in the PD GENEration registry.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: One patient, Bill, described his experience: diagnosed in his fifties after a physical therapist noticed a twitching thumb, he now runs, does yoga, and has enrolled in the PD GENEration registry.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Alpha-Synuclein Research: 25 Years Since Discovery
The critical role of alpha-synuclein in Parkinson's pathogenesis was discovered 25 years ago — still a milestone in PD research. Current approaches include antibodies targeting alpha-synuclein aggregates, gene therapies to reduce protein production, and small molecules designed to prevent misfolding. Research increasingly focuses on how alpha-synuclein interacts with other proteins and cellular machinery.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Research increasingly focuses on how alpha-synuclein interacts with other proteins and cellular machinery.
Limit: Results from cells or animals may not reproduce in people.
Hidden Protein Interaction Discovery Offers New Drug Target
Three years of investigation revealed that alpha-synuclein's abnormal binding to the ClpP enzyme is a key driver of mitochondrial dysfunction in Parkinson's. This interaction represents a novel drug target distinct from existing approaches. The Case Western team has already developed a prototype treatment blocking this interaction in cellular models. Generated daily from public research databases. For informational purposes only — not medical advice.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: For informational purposes only — not medical advice.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.